Search
Benitec Biopharma Inc
BNTCAdd to Watchlist
12.850USD
+0.550+4.47%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
441.45MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-23The current earnings forecast score of Benitec Biopharma Inc is 8.86, ranking 41 out of 389 in the Biotechnology & Medical Research industry. The average price target is 27.00, with a high of 32.00 and a low of 18.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
25.800
Target Price
+109.76%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Benitec Biopharma Inc
BNTC
6
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Benitec Biopharma Inc's price target?
Analysts forecast that Benitec Biopharma Inc's price target is USD 27.00, with the highest forecast at USD 32.00 and the lowest forecast at USD 18.00.
How have Benitec Biopharma IncBNTC's recent earnings per share performed?
The market expectation was USD -0.24, while Benitec Biopharma IncBNTC's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.28.
What is the analyst rating for Benitec Biopharma Inc?
Based on the ratings of Benitec Biopharma Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
